{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-110821","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.499258+00:00","generated_at":"2026-05-16T20:05:46.214371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Protalix Q3 revenue flat at $17.9M; net income down to $2.4M; PRX-115 phase 2 IND effective","bullets":["Q3 2025 revenue flat at $17.9M; net income $2.4M ($0.03 EPS) vs $3.2M ($0.04) in Q3 2024.","Nine-month 2025 revenue $43.6M (+24% YoY); net loss improved to $1.1M from $3.6M.","PRX-115 IND effective; phase 2 trial for uncontrolled gout planned for late 2025.","Chiesi requested re-examination of CHMP negative opinion on Elfabrio 2 mg/kg E4W; 1 mg/kg E2W still approved.","Cash and equivalents $29.4M at Sep 30, 2025; sufficient for at least 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-110821","json":"https://secwatch.observer/filing/0001104659-25-110821.json","markdown":"https://secwatch.observer/filing/0001104659-25-110821.md","text":"https://secwatch.observer/filing/0001104659-25-110821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000110465925110821/0001104659-25-110821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000110465925110821/plx-20251113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:05:46.214371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}